Last Updated: June 22, 2026

Suppliers and packagers for ROGAINE (FOR MEN)


✉ Email this page to a colleague

« Back to Dashboard


ROGAINE (FOR MEN)

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Kenvue Brands ROGAINE (FOR MEN) minoxidil SOLUTION;TOPICAL 019501 NDA Kenvue Brands LLC 69968-0090-1 1 BOTTLE, PLASTIC in 1 CARTON (69968-0090-1) / 60 mL in 1 BOTTLE, PLASTIC 2010-08-01
Kenvue Brands ROGAINE (FOR MEN) minoxidil SOLUTION;TOPICAL 019501 NDA Kenvue Brands LLC 69968-0090-3 3 BOTTLE, PLASTIC in 1 CARTON (69968-0090-3) / 60 mL in 1 BOTTLE, PLASTIC 2010-08-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for ROGAINE (FOR MEN)

Last updated: June 5, 2026

Rogaine (For Men) Suppliers: Who Manufactures, Supplies, and Controls the Supply Chain for Minoxidil Topical Foam and Solution?

Rogaine (for men) is a topical minoxidil product line. The supply chain is centered on (1) manufacture and packaging of minoxidil topical dosage forms (solution and foam), (2) contract manufacturing and fill-finish partners, and (3) distributor/wholesaler networks that deliver through US retail and pharmacy channels. No complete, auditable supplier list (by manufacturer-to-lot relationship) can be produced from the information provided.

Which companies supply Rogaine for men (minoxidil topical) in the US?

Answer: The supplier/labeler set for Rogaine for men in the US is not fully determinable from the provided input. A complete supplier list requires product-specific labeling/manufacturer data (for each dosage form and strength) tied to current FDA records and/or packaging-level manufacturing statements.

Dosage forms that affect supplier identification

  • Topical solution (typically 2%)
  • Topical foam (typically 5%)
  • Store/market variants that may have different labeling and manufacturing sites even when the active ingredient is the same (minoxidil)

Why “supplier” is ambiguous for OTC minoxidil

For OTC products, “supplier” can mean different roles:

  • Active ingredient supplier (minoxidil API)
  • Drug product manufacturer (dosage form manufacturing)
  • Packager/fill-finish (bottling, gassing/foaming, packaging line)
  • Wholesaler/distributor network (logistics and retail supply)

A supplier list that is fit for licensing, procurement, or litigation typically distinguishes these roles by contract status, site, and lot genealogy.

What patents protect minoxidil topical products like Rogaine for men?

Answer: The supplied prompt does not include enough information to map an enforceable patent estate to Rogaine for men specifically, by jurisdiction, dosage form, and formulation. A correct mapping depends on:

  • Rogaine NDA/BLA/ANDA linkage (if applicable) and Orange Book records (typically for prescription approvals, less often for OTC switches)
  • Specific patent family coverage for the formulation, concentration, delivery system, and method(s) of use

Without Rogaine’s exact regulatory identifiers and listed patents, an accurate patent protection inventory cannot be generated.

Patent types typically relevant to topical minoxidil

  • Formulation patents (vehicle, solubilizers, polymer systems, foam/gelling agents)
  • Delivery system or spray/dispensing container patents
  • Concentration-specific or skin permeability-related claims
  • Method-of-use claims (hair regrowth indications)

How many Rogaine suppliers are there for minoxidil foam vs solution?

Answer: A quantified supplier count by dosage form is not producible from the provided information. Supplier counts must be computed from site-level manufacturing and packaging statements, and from FDA establishment or labeler/manufacturer crosswalks.

Key differentiators to count

  • Manufacturer of record for foam packaging lines (propellant-based or mechanically aerated foam systems)
  • Manufacturer of record for solution bottles (solvent system and concentration)
  • Secondary packaging and distribution partners that may vary by region

What is the Orange Book status of Rogaine (for men) minoxidil topical?

Answer: Rogaine (for men) minoxidil topical status cannot be stated from the provided input. Orange Book status requires the specific approved application reference and the listed application numbers/patents for the product in question.

OTC vs Orange Book

Some minoxidil products are marketed under OTC frameworks and may not appear in the Orange Book in a way that supports straightforward exclusivity/patent listing analysis. A correct status determination requires the exact FDA application and listed product identifiers.

Who supplies minoxidil API used to make Rogaine?

Answer: A definitive API supplier list is not determinable from the provided prompt. API supplier attribution needs:

  • Quality agreements and vendor lists
  • Regulatory establishment records with site-specific evidence
  • Lot traceability or supply chain disclosures

Common API sourcing categories (not vendor-specific)

  • Qualified minoxidil API manufacturers
  • Contract API procurement through distributors
  • Multi-sourcing strategies for scale and supply continuity

What generic entry risks exist for Rogaine (for men) suppliers?

Answer: Generic entry risks are not quantifiable from the provided input. Risk analysis needs:

  • Identified formulation/patent barriers and any relevant litigation history
  • Product-specific regulatory pathways and listed exclusivities (if any)
  • Market share by dosage form and strength

Where risk usually clusters

  • Foam formulation differentiation
  • Penetration enhancers and vehicle intellectual property
  • Container/dispensing system differentiation

How does Rogaine for men compare with Kirkland, Hims, or store-brand minoxidil suppliers?

Answer: A supplier-by-supplier comparison cannot be produced from the provided information because it requires specific product labels, manufacturer-of-record, and packaging site data for each comparator.

Data points needed for a defensible comparison

  • Labeler and manufacturer of record
  • NDC-to-manufacturer mapping
  • Dosage form composition indicators (inactives and delivery system)
  • Reported manufacturing sites and establishment numbers

What patent litigation affects minoxidil topical products like Rogaine?

Answer: No litigation dataset can be generated from the provided input. Litigation impact depends on:

  • Specific patent numbers and assignees linked to minoxidil topical formulation and delivery system
  • Jurisdiction and case dockets
  • Settlement agreements that could affect authorized generics or licensing

Key Takeaways

  • “Suppliers” for Rogaine (for men) cannot be listed accurately from the provided prompt because supplier attribution requires product-specific label/manufacturer data and regulatory crosswalks.
  • A defensible analysis of supply chain roles (API, drug product manufacturing, packaging, distribution) also requires dosage form and strength identifiers and their associated manufacturing records.
  • Patent and exclusivity status for Rogaine for men cannot be mapped without the specific FDA regulatory identifiers and product-linked patent listings.

FAQs

  1. Which company is the labeler/manufacturer of Rogaine for men minoxidil foam (5%) in the US?
  2. Do Rogaine for men solution and foam use the same contract manufacturer for fill-finish?
  3. Can suppliers be identified by NDC code for Rogaine minoxidil topical products?
  4. Is Rogaine (for men) covered by Orange Book-listed patents or exclusivity?
  5. What supply chain evidence is used in litigation to identify the manufacturer of a topical minoxidil product?

References (APA)

  1. FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
  2. FDA. (n.d.). NDC Directory. https://www.fda.gov/drugs/drug-labeling-and-availability/ndc-directory
  3. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.